An interventional study of Wireless cardiac stimulator implant to pace the left ventricle for CRT in Heart Failure, Ventricular Dysfunction and Cardiomyopathy, sponsored by EBR Systems, Inc.. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-08.
Sponsored by EBR Systems, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 600 studies in Heart Failure with a site in Germany — 105 open to participants now, 136 under way, 19 of them phase 3. Heart Failure · Germany.
Among the 600 studies in Heart Failure with a site in Germany, this one is the 345th largest by enrollment of the 386 interventional ones that give a count, is one of 28 that started in 2011, is one of 175 with no phase, and was the 147th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →105 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Germany
Ages 18+
Stephan Baldus · Sites in Germany
Ages 18+
Jena University Hospital · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 29 more countries
Ages 18+
AstraZeneca · Sites in Germany, United States, Portugal and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
600 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 82 · Phase 3 91 · Phase 4 32
First in 1983; this study’s year is marked. 28 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 161 across the 386 interventional studies, 286 across the 212 observational. Of the 412 that completed or were terminated, 126 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
356 of 600 have an industry lead sponsor. The 10 most frequent:
EBR Systems, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
EBR Systems, Inc. has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
35 of the studies in Heart Failure with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07038356Phase 3Christian SchulzeEffects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure | 2027-04-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 35 to your calendar (.ics) → With an account.
Among the 600 studies in Heart Failure with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The WiCS-LV system is an alternative means to providing left ventricular stimulation for Cardiac Resynchronization Therapy (CRT). The purpose of this study is to evaluate the safety and performance of the WiCS-LV System in patients with indications for CRT.
Eligible patients will undergo an acoustic window assessment using transthoracic echocardiography. Patients with adequate acoustic windows will undergo implantation of the WiCS-LV system.
Patients will undergo evaluations pre-hospital discharge, and at one month, 3 months, and 6 months post implantation. Extended follow-up will be obtained via a registry at 1, 2, 3, 4, and 5 years post implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with standard indication for CRT based upon the most recent guidelines AND meeting criteria for one of these three categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implant of the WiCS-LV system
Device: Wireless cardiac stimulator implant to pace the left ventricle for CRT
Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
Also known as: WiCS-LV system
Number of patients with device-related adverse events as a measure of safety
Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.
Time frame: 24 hour peri-operative and one month
Number of patients with procedure-related adverse events as a measure of safety
Procedure-related adverse events are those which occur during the WiCS-LV system implant procedure.
Time frame: 24 hour perioperative and one month
Bi-ventricular pacing capture
Bi-ventricular pacing capture documented on 12-lead EKG
Time frame: one month
Number of patients with device-related adverse events as a measure of safety
Device-related adverse events are those in which the WiCS-LV system is directly or indirectly responsible.
Time frame: 6 months
Number of patients with serious adverse events as a measure of safety
Time frame: 6 months
Left ventricular pacing capture
Left ventricular pacing capture documented on 12-lead EKG
Time frame: 1, 3, and 6 months
Bi-ventricular pacing capture
Bi-ventricular pacing capture documented on 12-lead EKG
Time frame: 3 and 6 months
Bi-ventricular pacing capture
Bi-ventricular pacing capture on 24 hour ambulatory monitoring
Time frame: 1, 3, and 6 months
Clinical composite score
Composite of all cause mortality, heart failure hospitalization, NYHA class, and patient global assessment
Time frame: 6 months
Change in echocardiographic indices
change in left-ventricular end-systolic volume, left ventricular end-diastolic volume, and ejection fraction
Time frame: 6 months
Change in blood laboratory Brain Natriuretic Peptide
change in NT-proBNP level
Time frame: 6 months
The record gives a start of Feb 2011, a primary completion of Apr 2012 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EBR Systems, Inc.